Genfit (NASDAQ:GNFT) Trading Up 2% – Still a Buy?

Genfit S.A. (NASDAQ:GNFT)’s share price traded up 2% during trading on Tuesday . The stock traded as high as $4.75 and last traded at $4.62. 11,051 shares changed hands during mid-day trading, a decline of 26% from the average session volume of 14,856 shares. The stock had previously closed at $4.53.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Genfit in a report on Friday, February 7th.

Genfit Price Performance

The firm’s fifty day simple moving average is $3.57 and its 200-day simple moving average is $3.98. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61.

Hedge Funds Weigh In On Genfit

A hedge fund recently bought a new stake in Genfit stock. Millennium Management LLC purchased a new position in Genfit S.A. (NASDAQ:GNFT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of Genfit at the end of the most recent reporting period. 2.24% of the stock is owned by institutional investors and hedge funds.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.